Jennifer Schumann

Dr. Jennifer Schumann

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2022 in Journal of Analytical Toxicology
Verified
Journal Article
Closed access
PDF file
JSJennifer Schumann
Jennifer Schumann
RSRebekka Syrjanen
Rebekka Syrjanen
KAKatherine Alford
Katherine Alford
SMSrujana Mashetty
Srujana Mashetty
JCJared W Castle
Jared W Castle
SGShaun L Greene
Shaun L Greene
Benzimidazole synthetic opioids are highly potent μ-opioid receptor agonists with heroin-like effects, including dose-dependent respiratory depression and a high risk of abuse and toxicity. Benzimidazoles were first detected in 2019 in Europe and Canada, with analytical confirmation of etodesnitazene, protonitazene and butonitazene in 2021. We report the first detections of these compounds in Australia, in two patients presenting with drug toxicity to Emergency Departments (EDs) in the state of Victoria. Case 1 was a female in her 20s who rectally administered etodesnitazene and was found unconscious with respiratory depression and hypotension. Case 2 was a female in her 30s who presented to the ED in a sedated state after taking a formulation of protonitazene that also contained butonitazene, in addition to methylamphetamine. She responded positively to naloxone. Novel synthetic opioids were used with prior experience of the formulations purchased; however, the unpredictability of their effects was demonstrated by the acute toxicity experienced with this occasion of use. Toxicosurveillance of ED presentations with analytical confirmation of drugs is crucial in identifying emerging drugs in the community and informing harm reduction strategies.

1 April 2021 in Accident Analysis & Prevention
Verified
Journal Article
Closed access
JSJennifer Schumann
Jennifer Schumann
MPMonica Perkins
Monica Perkins
PDPaul Dietze
Paul Dietze
DNDhanya Nambiar
Dhanya Nambiar
BMBiswadev Mitra
Biswadev Mitra
BBBen Beck
Ben Beck

18 March 2025 in Addiction
Verified
Journal Article
Open access
RBRichard Bade
Richard Bade
DNDhayaalini Nadarajan
Dhayaalini Nadarajan
WHWayne Hall
Wayne Hall
JBJared A. Brown
Jared A. Brown
NCNPS Wastewater Consortium
NPS Wastewater Consortium
JSJennifer Schumann
Jennifer Schumann
Background and Aims: The use of new synthetic opioids, such as the highly potent 2‐benzylbenzimidazoles (i.e. nitazene) drugs, is a global health concern because of their increased risk of fatal overdose. In the early 2020s, nitazene analogues were linked to significant numbers of overdoses in the United States. Their reach is now worldwide, with nitazene overdose deaths reported in Europe, Australia and New Zealand. The aim of this study was to measure quantities of nitazenes in wastewater samples collected from 68 locations in 22 countries, covering six continents, to understand and estimate their use.Methods: Untreated influent wastewater samples were collected over a one‐week period that included the New Year period in 2022–2023 and 2023–2024. Samples were collected from 22 countries: Australia, Austria, Belgium, Brazil, Canada, Chile, China, Cyprus, Czechia, France, Germany, Greece, Iceland, Italy, New Zealand, Nigeria, Republic of Korea, Slovenia, Spain, Sweden, United Kingdom and United States. Samples were loaded onto solid‐phase extraction cartridges in the country of collection and sent to Australia for elution and analysis using sensitive liquid chromatography–mass spectrometry methods.Results: A total of 683 individual wastewater samples were analysed across the two years: 339 in 2022–2023 and 344 in 2023–2024. Two nitazene analogues—protonitazene and N‐pyrrolidino etonitazene (etonitazepyne)—were found in five separate sites in the United States and Australia. In the 2022–2023 period, protonitazene was found in two sites in the United States. The following year, protonitazene was detected in two further sites in the United States, while both protonitazene and etonitazepyne were found in one site in Australia. Protonitazene mass loads ranged between 0.3 mg/day/1000 people and 100 mg/day/1000 people. Etonitazepyne was also found at mass loads between 0.2–2 mg/day/1000 people).Conclusions: A very high mass load of protonitazene was calculated, using wastewater analysis, for the day of 30 December 2023 in one site in Australia. Etonitazepyne showed the same trend from a lower base. Wastewater‐based nitazene surveillance shows promise as a form of both drug early warning and ongoing monitoring of trends in use, especially as a complementary tool to existing surveillance methods.

19 January 2025 in Drug and Alcohol Review
Verified
Journal Article
Closed access
KIKatherine Z Isoardi
Katherine Z Isoardi
SASam Alfred
Sam Alfred
CWCourtney Weber
Courtney Weber
KHKeith Harris
Keith Harris
JSJessamine Soderstrom
Jessamine Soderstrom
EIEDNA and EDNAV Investigators
EDNA and EDNAV Investigators

30 July 2024 in Clinical Toxicology
Verified
Journal Article
Closed access
RSRebekka Syrjanen
Rebekka Syrjanen
JSJennifer Schumann
Jennifer Schumann
JCJared Castle
Jared Castle
LSLesley Sharp
Lesley Sharp
AGAndrew Griffiths
Andrew Griffiths
SGShaun L. Greene
Shaun L. Greene
Protonitazene is an opioid belonging to the 2-benzylbenzimidazole structural class. We describe two cases of opioid toxicity involving the reported inhalation of a delta-9-tetrahydrocannabinol vape product in which protonitazene was detected. Case 1 was a young male found unconscious after the reported use of a delta-9-tetrahydrocannabinol vape. He suffered two subsequent apnoeic episodes requiring bag-valve-mask ventilation before eventual recovery. Only protonitazene was detected in blood at a concentration of 0.74 µg/L. Case 2 was a young male who died shortly after being found unresponsive. The postmortem femoral blood concentrations of protonitazene and delta-9-tetrahydrocannabinol were 0.33 µg/L and 2 µg/L, respectively. Analysis of a pod vaping device found in the decedent's hand and a separate e-liquid bottle labelled as delta-9-tetrahydrocannabinol showed a mixture of protonitazene and delta-9-tetrahydrocannabinol. The opioid effects of protonitazene are mediated through β-arrestin2 and mu opioid receptor signalling pathways. Benzimidazole opioids are lipophilic and, when mixed with a suitable solvent, can be used in a vape device. It is anticipated that naloxone would have provided effective reversal of toxicity in our cases. Novel routes of opioid administration, like vaping, may appear relatively innocuous in comparison to intravenous administration, but opioids may still be absorbed at high concentrations, resulting in severe opioid toxicity or death.

7 November 2023 in International Journal of Drug Policy
Verified
Journal Article
Closed access
RSRebekka Syrjanen
Rebekka Syrjanen
SGShaun L. Greene
Shaun L. Greene
CWCourtney Weber
Courtney Weber
JSJennifer L. Smith
Jennifer L. Smith
SHSarah E. Hodgson
Sarah E. Hodgson
JSJennifer Schumann
Jennifer Schumann